- Home
- NIM vs XFOR Comparison
NIM vs XFOR Comparison
Compare NIM & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIM
- XFOR
- Stock Information
- Founded
- NIM 1992
- XFOR 2014
- Country
- NIM United States
- XFOR United States
- Employees
- NIM N/A
- XFOR N/A
- Industry
- NIM Trusts Except Educational Religious and Charitable
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIM Finance
- XFOR Health Care
- Exchange
- NIM Nasdaq
- XFOR Nasdaq
- Market Cap
- NIM 112.4M
- XFOR 118.4M
- IPO Year
- NIM N/A
- XFOR N/A
- Fundamental
- Price
- NIM $9.18
- XFOR $1.94
- Analyst Decision
- NIM
- XFOR Strong Buy
- Analyst Count
- NIM 0
- XFOR 3
- Target Price
- NIM N/A
- XFOR $72.33
- AVG Volume (30 Days)
- NIM 35.4K
- XFOR 476.1K
- Earning Date
- NIM 01-01-0001
- XFOR 08-07-2025
- Dividend Yield
- NIM 3.46%
- XFOR N/A
- EPS Growth
- NIM N/A
- XFOR N/A
- EPS
- NIM N/A
- XFOR 2.16
- Revenue
- NIM N/A
- XFOR $31,364,000.00
- Revenue This Year
- NIM N/A
- XFOR $1,106.53
- Revenue Next Year
- NIM N/A
- XFOR N/A
- P/E Ratio
- NIM N/A
- XFOR $0.87
- Revenue Growth
- NIM N/A
- XFOR N/A
- 52 Week Low
- NIM $8.28
- XFOR $1.81
- 52 Week High
- NIM $9.74
- XFOR $26.96
- Technical
- Relative Strength Index (RSI)
- NIM 64.93
- XFOR 29.89
- Support Level
- NIM $8.95
- XFOR $1.81
- Resistance Level
- NIM $9.01
- XFOR $2.12
- Average True Range (ATR)
- NIM 0.07
- XFOR 0.24
- MACD
- NIM 0.03
- XFOR -0.03
- Stochastic Oscillator
- NIM 89.29
- XFOR 6.72
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.